Latest News
GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race
Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...
Latest News
Burning from the Inside Out: When Strong Values Become Burnout Risks
Is Burnout More Than Workload? Are external pressures the only drivers of burnout, or can self-perception and the manipulation of values also play a role? Burnout, nervous system regulation, and boundaries have become increasingly familiar concepts within...
The Sourcing Channel Moved East
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
Parkinson’s Research Field is Approaching a Pivotal Moment
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Base Editing vs CRISPR: What’s the Difference and Why Does it Matter?
In May 2026, a single intravenous infusion reduced LDL cholesterol by up to 62% in patients with a genetic condition that no statin could adequately control. No repeat dosing was required. No serious adverse events were reported. The therapy, VERVE-102, was not a...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
Invisible Architect: How Infrastructure Drives Life Sciences Growth
In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...
CagriSema: The Next Big Obesity Drug? What the Phase 3 Data Shows
The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
Weekly News Roundup | 11 May 2026
Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...
Why “Hot” Therapeutic Areas Break Traditional Benchmarks
In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...
Is Photodisinfection the New Alternative to Traditional Antibiotics?
Few ideas in modern medicine are as unsettling as the prospect of a “post-antibiotic era.” For decades, antibiotics have underpinned infection control, transforming once-lethal diseases into manageable conditions. Yet their effectiveness is steadily eroding....
Orforglipron Approved: Inside the Oral GLP-1 Race
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
Clinical Trials Roundup | 8 May 2026
Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...
GSK Secures $1bn Rights to SiranBio siRNA Therapy
GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company's early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential...
From Wrist to Ward: Which Wearables Have Earned Clinical Trust
The wearable health technology market has expanded at a pace that regulators, clinicians, and patients have struggled to keep up with. Smartwatches, adhesive biosensors, continuous glucose monitors, and cardiac patches are now part of the fabric of daily life for...
Why Innovation in Oncology Diagnostics Is An Imperative We Must Prioritize
Not long ago, I spoke with a colleague, a mother named Kelley who has spent the past two years asking a question that increasingly reflects a broader challenge in oncology: If technologies exist to detect cancer earlier, why aren’t we dedicating more effort to support...
India, Brazil and Southeast Asia: The New Pharma Powerhouses
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
Invisible Architect: How Infrastructure Drives Life Sciences Growth
In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...
CagriSema: The Next Big Obesity Drug? What the Phase 3 Data Shows
The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
Weekly News Roundup | 11 May 2026
Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...
Why “Hot” Therapeutic Areas Break Traditional Benchmarks
In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...
Is Photodisinfection the New Alternative to Traditional Antibiotics?
Few ideas in modern medicine are as unsettling as the prospect of a “post-antibiotic era.” For decades, antibiotics have underpinned infection control, transforming once-lethal diseases into manageable conditions. Yet their effectiveness is steadily eroding....
Orforglipron Approved: Inside the Oral GLP-1 Race
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
Clinical Trials Roundup | 8 May 2026
Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...
GSK Secures $1bn Rights to SiranBio siRNA Therapy
GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company's early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential...
From Wrist to Ward: Which Wearables Have Earned Clinical Trust
The wearable health technology market has expanded at a pace that regulators, clinicians, and patients have struggled to keep up with. Smartwatches, adhesive biosensors, continuous glucose monitors, and cardiac patches are now part of the fabric of daily life for...
Why Innovation in Oncology Diagnostics Is An Imperative We Must Prioritize
Not long ago, I spoke with a colleague, a mother named Kelley who has spent the past two years asking a question that increasingly reflects a broader challenge in oncology: If technologies exist to detect cancer earlier, why aren’t we dedicating more effort to support...
India, Brazil and Southeast Asia: The New Pharma Powerhouses
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
Featured Articles
Further News
Paediatric Trials: Why Children Remain Therapeutic Orphans
Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...
Global Nursing Shortage: The Life Sciences Risk
For the life sciences sector, the global nursing shortage is not a background public health concern. It is a clinical trial staffing problem, a pharmaceutical market access problem, and a real-world evidence problem. The WHO's 2025 State of the World's Nursing report...
Why Clinical Trial Diversity Remains a Problem
For decades, clinical trials have failed to adequately represent the patients who will ultimately use the medicines and treatments being tested. Gaps in enrolment across race, ethnicity, sex, age, and socioeconomic background have created an incomplete evidence base,...
Weekly News Roundup | 4 May 2026
Life science news 4 May 2026: Eli Lilly's record $19.8 billion quarterly earnings, the FDA's real-time clinical trial revolution and a landmark week for UK regulatory reform define a momentous seven days for global life science. Eli Lilly reported worldwide revenue of...
The Gap Between Precision Medicine and Clinical Reality
Precision medicine is no longer a futuristic concept. Genomic panels, pharmacogenomic testing, advanced biomarker analysis, and individualized risk stratification tools are all available today. Yet for the vast majority of patients walking into a primary care office,...
Clinical Trials Roundup | 1 May 2026
Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in...
Longevity Biotech: Separating the Science from the Hype
The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...
Sun Pharma’s $11.75bn Organon Deal Reshapes Global Pharma
India's largest pharmaceutical company, Sun Pharmaceutical Industries, has agreed to acquire New Jersey-based Organon & Co. in an all-cash transaction valued at $11.75 billion, marking the largest acquisition ever undertaken by an Indian biopharmaceutical company....
Report Finds Seven in Ten Leaders Bullied by Their Teams
Healthcare organisations invest significantly in psychosocial risk frameworks, governance structures and leadership development. Yet a new international study highlights a type of organisational risk that most of those frameworks are not designed to detect. It is a...
How Traditional Japanese Wisdom can Bridge the Cardiovascular Health Gap
For decades, the global medical community has looked to Japan with a sense of wonder, specifically regarding the Japanese paradox of longevity. Epidemiological data consistently highlights a significant cardiovascular health gap between Japan and Western nations like...
Speech Could be a Key Marker in Neurodegenerative Disease Drug Trials
Speech is rapidly emerging as an important, non-invasive, digital clinical marker in neurodegenerative disease research, according to leading biotech SynaptixBio. The company has facilitated a study run by Australia-based speech analytics company Redenlab, in...
How AI-Driven Research is Reshaping Competitive Intelligence in Pharma
AI developments are happening at breakneck speed, with every sector and industry seeking new opportunities to seize and capitalise upon. AI-driven research is creating a fundamental shift for pharmaceutical competitive intelligence, moving away from a reactive, manual...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.